Poor prognosis for breast cancer detected after negative mammography
New Harvard-led research indicates that cases of breast cancer diagnosed after a negative screening mammogram were more likely to be associated with poor prognosis than those cancers diagnosed after a positive screening mammogram. The findings were based on a review and analysis of mammography data for more than 300,000 women and published in JAMA Oncology.
"The rate of breast cancer after negative mammography results is small but the likelihood these cases can be associated with poor prognosis highlights the need for early detection," write Anne Marie McCarthy, PhD, Department of Medicine, Massachusetts General Hospital and Harvard Medical School in Boston, and co-authors.
Approximately 15 percent of breast cancers are diagnosed after the patient undergoes screening mammography with negative results and before the next recommended screening examination. These interval cancers (cases of cancer diagnosed during the interval between examinations) include both cancers that were present during screening mammography but were missed on examination and rapidly growing cancers that present symptomatically and tend to have a poorer prognosis than cancers detected during screening.
McCarthy and collegues conducted this observational study to determine the incidence of and risk factors associated with breast cancer with a poor prognosis after screening mammography with negative findings. Mammography data were obtained from the Population-Based Research Optimising Screening Through Personalised Regimens (PROSPR) consortium.
The study population (n = 306,028) included women 40 years or older with no earlier diagnosis of breast cancer who received screenng mammography between 2011 and 2014. Mammograms with negative results were those with an initial Breast Imaging Reportng and Data System category 1 or 2; mammograms in all other categories were classified as having positive results. Cancer diagnoses within one year after screening mammography were obtained from state cancer registries. Breast cancer cases with a poor prognosis were defined as those meeting any of the following criteria: distant metastases; cancer-positive regional lymph nodes; estrogen receptor-positive and/or progesterone receptor-positive and HER2-negative invasive cancer 2 cm or more in diameter; estrogen receptor-negative, progesterone receptor-negative; HER2-negative (triple-negative) invasive cancer 1 cm or more in diameter; or HER2-positive cancer 1 cm or more in diameter.
The results show that cases of cancer diagnosed after screening mammography with negative results were more likely to be associated with a poor prognosis (43.8 percent) than those diagnosed after mammography with positive results (26.9 percent). Among all women with a negative mammogram, women with dense breasts had twice the odds of receiving a cancer diagnosis (irrespective of prognosis) with women with nondense breasts. Age and family histor were not significantly associated with breast cancer diagnosis after negative mammography results.
"However, among women who received a diagnosis of cancer after negative mammography results, younger age was associated with having cancer with a poor prognosis," the authors note. "Breast density and family history were not significantly associated with poor prognosis."
Source: JAMA Oncology
Image Credit: Pixabay
Published on : Tue, 8 May 2018
Sectra's reporting module, developed with complex oncology cases in mind, facilitates overview of relevant priors together with the current request and report text. It also offers support for resident workflows and embedded links to images in the rep...
UltraDrape is an innovative dressing designed for use during Ultrasound-Guided Peripheral Intravenous (UGPIV) that provides dual-action barrier and securement in one.
The Next Evolution in Ultrasound, designed for high expectations ARIETTA 850 ultrasound platform responds to high expectations to answer the ever increasing demands of medical professionals. ARIETTA 850’s fundamental performance has been refined...
The SonoSite SII features a new touchscreen user interface with a clinician-driven menu logic that adaptively adjusts to your imaging needs – “what you need, is what you see”. An embedded dual transducer connector allows you to quickly switch between...
THE VEVO MD IS THE WORLD’S FIRST ULTRA HIGH FREQUENCY ULTRASOUND SYSTEM DESIGNED FOR CLINICAL USE WITH FREQUENCIES UP TO 70 MHz. This groundbreaking technology opens up new possibilities for medical imaging that have never been seen before. Whether...